Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Codeine→

Codeine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
76-57-3
Molecular formula
C18H21NO3
Molecular weight
299.4 g/mol
Drug class
BarbiturateCentral Nervous System StimulantMethylxanthineBarbituratesXanthinesCentral Nervous System StimulationNonsteroidal Anti-inflammatory DrugPlatelet Aggregation InhibitorAnti-Inflammatory Agents, Non-SteroidalDecreased Prostaglandin ProductionDecreased Platelet AggregationExpectorant
Mechanism of action
Cyclooxygenase Inhibitors [MoA]
Indications / reported uses
  • Cough
  • Pain
  • mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate
  • the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate
  • the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesic and alternative treatments are inadequate

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Codeine Environmental Risk Assessment (ERA) (the Codeine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.